Ascletis Pharma's ASC30, a novel oral GLP-1 receptor agonist, demonstrated dose-proportional pharmacokinetics and a long half-life of up to 60 hours in a Phase Ia study.
Ascletis' ASC47, combined with semaglutide, demonstrated a 56.7% greater reduction in body weight compared to semaglutide alone in diet-induced obese mice.
Ascletis has initiated two Phase I clinical trials in the U.S. for ASC30, a small molecule GLP-1R agonist, offering both once-monthly subcutaneous injection and once-daily oral tablet options for obesity treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.